Alnylam Pharmaceuticals(US:ALNY)2025-10-30 12:30Financial Performance - Total net product revenues reached $851 million in Q3 2025, representing a 103% year-over-year growth compared to Q3 2024[17, 24] - Total TTR net revenues were $724 million in Q3 2025, a 135% increase year-over-year[17, 31] - U S total TTR net revenues amounted to $543 million in Q3 2025, demonstrating a 194% year-over-year growth[17] - The company increased its 2025 total net product revenue guidance to a range of $2950 million to $3050 million, a 10% increase at the midpoint[17] - Non-GAAP operating income was $476 million, resulting in a 38% non-GAAP operating margin[65] Product Performance - Rare disease franchise revenues totaled $127 million in Q3 2025, a 14% increase year-over-year[28] - OXLUMO sales grew by 31% year-over-year, driven by a 15% increase in global patients on therapy[29] - AMVUTTRA's ATTR-CM launch contributed significantly to growth, with estimated ATTR-CM revenue of approximately $300 million in Q3 2025 in the U S [33, 34] Pipeline and Clinical Development - Phase 3 trial initiated for nucresiran in ATTR-CM, with topline results expected in 2028 and targeting launch around 2030[17, 47] - Phase 3 cardiovascular outcomes trial (CVOT) initiated for zilebesiran in high cardiovascular risk patients with uncontrolled hypertension, randomizing approximately 11,000 patients[17, 56] - HELIOS-B data showed a 37% risk reduction in time-to-first ACM and CV events with long-term vutrisiran treatment[43]